自体造血干细胞移植治疗急性白血病50例临床研究  

Treatment of 50 Acute Leukemia Patients with Autologous Hematopoietic Stem Cell Transplantation

作　　者：刘海川[1] 姚善谦[1] 楼方定[1] 彭矞云[1] 周绮[1] 朱军[1] 闰影[1] 王连元[1] 

机构地区：[1]解放军总医院,北京100853

出　　处：《中国肿瘤生物治疗杂志》1995年第1期50-52,共3页Chinese Journal of Cancer Biotherapy

摘　　要：本文报告自体造血干细胞移植治疗急性白血病50例,其中,未净化自体骨髓移植(ABMT)10例,净化后自体骨髓移植(PABMT)22例,自体外周血干细胞移植(ASHSCT)18例.3年无病生存率,3组分别为75%、69.9%、72.7%.复发率分别为36.6%、27.2%、31.4%.确诊到缓解(CR)时间<2月、CR到移植时间>6月、预处理方案化疗放疗(TBI)及急性髓细胞白血病(AML)3年无病生存率较高,复发率较低.We treated 50 acute leukemia patients with autologous hematopoietic stem cell transplantation. Among them, 10 patients were transplanted with unpurged autologous bone marrow (ABMT), 22 patients with purged autologous bone marrow(PABMT), 18 Patients with autologous blood hematopoietic stem cell (ABHSCT). The three years disease-free living incidences in the three groups were 75%,69.9% and 72.7%, respectively. The relapse rates were 36.6%, 27.2%, and 31.4%, respectively.A high three-year disease-free incidence and low relapse rate were found in the patients with less than two months between diagnosis and achieving complete remission (CR), transplantation after 6 months of achieving CR, conditioning treatment with chemotherapy and total body irradiation (TBI) and acute myeloid leukemia (AML). The results indicated that there are some correlations between the amount of infused mononuclear cells and the recovery of bone marrow hematopoiesis. No significant difference of therapeutic effiency was demonstrated among the three groups.

关 键 词：治疗 自体造血干细胞移植 急性白血病 无病生存率 复发率 临床研究 CR 组分 净化 AML 

分 类 号：R733[医药卫生—肿瘤] R735.7[医药卫生—临床医学]